The toxicity and pathology of selected dietary herbal medicines

Toxicologic Pathology

Volumn 41, Issue 2, 2013, Pages 374-386

  Dunnick, June K ^a   Nyska, Abraham ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aloe vera whole leaf nondecolorized extract; ginkgo; ginseng; goldenseal; kava kava; milk thistle; turmeric oleoresin

Indexed keywords

ALOE BARBADENSIS EXTRACT; CURCUMA LONGA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYDRASTIS CANADENSIS EXTRACT; KAVA EXTRACT; PLANT EXTRACT; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG;

ALOE VERA; ARTICLE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CHEMICAL COMPOSITION; CURCUMA LONGA; DIET SUPPLEMENTATION; DRUG CARCINOGENICITY; DRUG EXPOSURE; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; GINKGO BILOBA; GINSENG; HERBAL MEDICINE; HISTOPATHOLOGY; HUMAN; HYDRASTIS; INTESTINE TUMOR; LIVER TOXICITY; LIVER TUMOR; LONG TERM EXPOSURE; NONHUMAN; PIPER METHYSTICUM; PLANT LEAF; PLANT ROOT; PRIORITY JOURNAL; SILYBUM MARIANUM; THYROID TUMOR; TOXICITY TESTING;

ANIMALS; DIETARY SUPPLEMENTS; HUMANS; LIVER; LIVER NEOPLASMS; PLANT EXTRACTS; PLANTS, MEDICINAL; TOXICITY TESTS;

ALOE VERA; CURCUMA LONGA; HYDRASTIS CANADENSIS; MUS; PANAX GINSENG; PIPER METHYSTICUM; RATTUS; RODENTIA; SILYBUM MARIANUM;

EID: 84875728723     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312466451     Document Type: Article

References (60)

1. Ahn A. C., Nahin R. L., Calabrese C., Folkman S., Kimbrough E., Shoham J., Haramati A.. Applying principles from complex systems to studying the efficacy of CAM therapies. J Altern Complement Med. 2010 ; 16: 1015-22
2. Allen D. G., Pearse G., Haseman J. K., Maronpot R. R.. Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol. 2004 ; 32: 393-401
3. Auerbach S. S., Shah R. R., Mav D., Smith C. S., Walker N. J., Vallant M. K., Boorman G. A., Irwin R. D.. Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol. 2010 ; 243: 300-14
4. Bailer A. J., Portier C. J.. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics. 1988 ; 44: 417-31
5. BarnesP. M.BloomB.NahinR. L. (2008). Complementary and alternative medicine use among adults and children: United States, 2007. National Health Statistics Reports12, available from NCCAM website, accessed December 10, 2008, http://nccam.nih.gov/news/camstats.htm.
6. Boorman G. A., Eustis S. L. Managing Conduct and Data Quality of Toxicologic Studies. Whitmire C. Davis C. L. Bristol D. W., ed. Princeton, NJ: Princeton Scientific Publishing ; 1986: 271-75.
7. Brusick D., Mengs U.. Assessment of the genotoxic risk from laxative senna products. Envirn Mol Mutagen. 1997 ; 29: 1-9
8. Cohen P. A.. American roulette - Contaminated dietary supplements. N Engl J Med. 2009 ; 361: 1523-25
9. Damsch S., Eichenbaum G., Looszova A., Lammens L., Feyen B., Van den Bulck K., Knight E., Kelley M., Tonelli A.. Unexpected nasal changes in rats related to reflux after gavage dosing. Toxicol Pathol. 2011a ; 39: 337-47
10. Damsch S., Eichenbaum G., Tonelli A., Lammens L., Van den Bulck K., Feyen B., Vandenberghe J., Megens A., Knight E., Kelley M.. Gavage-related reflux in rats: Identification, pathogenesis, and toxicological implications (review). Toxicol Pathol. 2011b ; 39: 348-60
11. Diwan B. A., Henneman J. R., Rice J. M.. Further evidence for promoter-dependent development of hepatoblastoma in the mouse. Cancer Lett. 1995 ; 89: 29-35
12. El-Kamary S. S., Shardell M. D., Abdel-Hamid M., Ismail S., El-Ateek M., Metwally M., Mikhail N., Hashem M., Mousa A., Aboul-Fotouh A., El-Kassas M., Esmat G., Strickland G. T.. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009 ; 16: 391-400
13. Fielden M. R., Adai A., Dunn R. T., Olaharski A., Searfoss G., Sina J., Aubrecht J., Boitier E., Nioi P., Auerbach S., Jacobson-Kram D., Raghavan N., Yang Y., Kincaid A., Sherlock J., Chen S. J., Car B.. Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol Sci. 2011 ; 124: 54-74
14. Griesser M., Pistis V., Suzuki T., Tejera N., Pratt D. A., Schneider C.. Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. J Biol Chem. 2011 ; 286: 1114-24
15. Gupta S. C., Patchva S., Koh W., Aggarwal B. B.. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012 ; 39: 283-99
16. Gupta S. C., Prasad S., Kim J. H., Patchva S., Webb L. J., Priyadarsini I. K., Aggarwal B. B.. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011 ; 28: 1937-55
17. Hardisty J. G., Boorman G. A. Managing Conduct and Data Quality of Toxicologic Studies. Whitmire C. Davis C. L. Bristol D. W., ed. Princeton, NJ: Princeton Publishing Company ; 1986: 263-69.
18. Hawke R. L., Schrieber S. J., Soule T. A., Wen Z., Smith P. C., Reddy K. R., Wahed A. S., Belle S. H., Afdhal N. H., Navarro V. J., Berman J., Liu Q. Y., Doo E., Fried M. W.. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2011 ; 50: 434-49
19. He B. C., Gao J. L., Luo X., Luo J., Shen J., Wang L., Zhou Q., Wang Y. T., Luu H. H., Haydon R. C., Wang C. Z., Du W., Yuan C. S., He T. C., Zhang B. Q.. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ss-catenin signaling. Int J Oncol. 2011 ; 38: 437-45
20. Hill R. N., Crisp T. M., Hurley P. M., Rosenthal S. L., Singh D. V.. Risk assessment of thyroid follicular cell tumors. Environ Health Perspect. 1998 ; 106: 447-57
21. Hoenerhoff M. J., Pandiri A. R., Lahousse S. A., Hong H. H., Ton T. V., Masinde T., Auerbach S. S., Gerrish K., Bushel P. R., Shockley K. R., Peddada S. D., Sills R. C.. Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: Similarities in the molecular landscape with human liver cancer. Toxicol Pathol. 2011 ; 39: 678-99
22. Holsapple M. P., Pitot H. C., Cohen S. M., Boobis A. R., Klaunig J. E., Pastoor T., Dellarco V. L., Dragan Y. P.. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 2006 ; 89: 51-6
23. IARC Mongrap 100A, A review of human carcinogens: Pharmaceuticals. IARC Mongraphs on the Evaluation of Carcinogenic Risks to Humans. 2011 ; 100A :
24. Kim J. W., Jung S. Y., Kwon Y. H., Lee J. H., Lee Y. M., Lee B. Y., Kwon S. M.. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol Ther. 2012 ; 13 :
25. Kobayashi Y., Yamashita Y., Fujii N., Takaboshi K., Kawakami T., Kawamura M., Mizukami T., Nakano H.. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med. 1995 ; 61: 414-18
26. Lichtenstein P., Holm N. V., Verkasalo P. K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K.. Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 ; 343: 78-85
27. Luo X., Wang C. Z., Chen J., Song W. X., Luo J., Tang N., He B. C., Kang Q., Wang Y., Du W., He T. C., Yuan C. S.. Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol. 2008 ; 32: 975-83
28. Makhey D., Gatto B., Yu C., Liu A., Liu L. F., LaVoie E. J.. Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topisomerase I and II. Med Chem Res. 1994 ; 5: 1-12
29. Maronpot R., Yoshizawa K., Nyska A., Harada T., Flake G., Muyeller G., Singh B., Ward J.. Hepatic enzyme induction: Histopathology. Toxicol Pathol. 2010 ; 38: 776-95
30. Miranda S. R., Lee J. K., Brouwer K. L., Wen Z., Smith P. C., Hawke R. L.. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: Role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab Dispos. 2008 ; 36: 2219-26
31. Morales M. A., Hernandez D., Bustamante S., Bachiller I., Rojas A.. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity?. J Toxicol. 2009 ; 2009: 287247
32. Mori H., Sugie K., Niwa M., Takahashi M., Kawai K.. Induction of intestinal tumours in rats by chrysazin. Br J Cancer. 1985 ; 52: 781-83
33. Mori H., Sugie S., Niwa K., Yoshimi N., Tanaka T., Hirono I.. Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn J Cancer Rese (GANN). 1986 ; 77: 871-76
34. Mori H., Yoshimi N., Iwata H., Mori Y., Hara A., Tanaka T., Kawai K.. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: Induction of large bowel, liver and stomach neoplasms. Carcinogenesis. 1990 ; 11: 799-802
35. Nag S. A., Qin J. J., Wang W., Wang M. H., Wang H., Zhang R.. Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol. 2012 ; 3: 25
36. Nahin R. L., Dahlhamer J. M., Stussman B. J.. Health need and the use of alternative medicine among adults who do not use conventional medicine. BMC Health Serv Res. 2010 ; 10: 220
37. NIH (National Institutes of Health) (2011). ClinicalTrials.gov. http://www.clinicaltrials.gov/. Accessed December 2011.
38. NIH Office of Dietary Supplements (2011). Kava. http://ods.od.nih.gov/ Health-Information/kava.aspx. Accessed December 2011.
39. NTP toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) (major component 79%-85% curcumin, CAS No. 458-37-7) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Progr Tech Rep Ser. 1993 ; 427: 1-275
40. Toxicology and carcinogenesis studies of Emodin (Cas.No. 518-82-1) feed studies in F344/N rats and B6C3F1 mice. Technical Report. 2001 ; 493 :
41. Toxicology and carcinogenesis studies of Goldenseal root powder (Hydrastis canadensis) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Progr Tech Rep Ser. 2010 ; 562: 1-188
42. NTP toxicology and carcinogenesis studies of whole leaf extract of aloe barbadensis miller (Aloe vera) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Progr Tech Rep Ser. 2011a ; 577: 1-293
43. NTP toxicology and carcinogenesis studies of ginseng(CAS No. 50647-08-0) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Progr Tech Rep Ser. 2011b ; 567: 1-150
44. NTP toxicology and carcinogenesis studies of if kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Progr Tech Rep Ser. 2011c ; 571: 1-186
45. Toxicology and carcinogenesis studies of milk thstle extract (CAS No. 84604-20-6) in F344/N rats and B6c3f1 mice (Gavage Studies). Natl Toxicol Progr Tech Rep Ser. 2011d ; 564: 1-178
46. NTP toxicology and carcinogenesis studies of Ginkgo biloba extract CAS No. 90045-35-6) in F344/N rats and B6C3F1 mice (Feed Studies. Natl Toxicol Progr Tech Rep Ser. 2012 ; 578: 1-224
47. Pandiri A. R., Sills R. C., Hoenerhoff M. J., Peddada S. D., Ton T. V., Hong H. H., Flake G. P., Malarkey D. E., Olson G. R., Pogribny I. P., Walker N. J., Boudreau M. D.. Aloe vera non-decolorized whole leaf extract-induced large intestinal tumors in F344 rats share similar molecular pathways with human sporadic colorectal tumors. Toxicol Path. 2011 ; 39: 1065-74
48. Piegorsch W. W., Bailer A. J. Hall C. A., ed. London: Chapman and Hall ; 1997 :
49. Portier C. J., Bailer A. J.. Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam Appl Toxicol. 1989 ; 12: 731-37
50. Reed C. J.. Drug metabolism in the nasal cavity: Relevance to toxicology. Drug Metab Rev. 1993 ; 25: 173-205
51. Schrieber S. J., Hawke R. L., Wen Z., Smith P. C., Reddy R., Wahed A. S., Belle S. H., Afdhal N. H., Navarro V. J., Meyers C. M., Doo E., Fried M. W.. Differences in the disposition of silymarin between patients with non-alcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2010 ;:
52. Schrieber S. J., Wen Z., Vourvahis M., Smith P. C., Fried M. W., Kashuba A. D., Hawke R. L.. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008 ; 36: 1909-16
53. Sells D. M., Brix A. E., Nyska A., Jokinen M. P., Orzech D. P., Walker N. J.. Respiratory tract lesions in noninhalation studies. Toxicol Pathol. 2007 ; 35: 170-7
54. Shen L., Ji H. F.. The pharmacology of curcumin: Is it the degradation products?. Trends Mol Med. 2012 ; 18: 138-44
55. Sung B., Prasad S., Yadav V. R., Aggarwal B. B.. Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer. 2012 ; 64: 173-97
56. Turusov V. S., Torii M., Sills R. C., Willson G. A., Herbert R. A., Hailey J. R., Haseman J. K., Boorman G. A.. Hepatoblastomas in mice in the US National Toxicology Program (NTP) studies. Toxicol Pathol. 2002 ; 30: 580-91
57. U.S. Food and Drug Administration (2002). Consumer Advisory: Kava-Containing Dietary Supplements may be Associated with Sever Liver Injury. http://www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.htm. Accessed December 2011.
58. U.S. Food and Drug Administration (2011). Regulatory Framework of DSHEA of 1994. http://www.fda.gov/NewsEvents/Testimony/ucm115163.htm. Accessed June 2012.
59. U.S. Food and Drug Administration (2012). Dietary Supplement Health and Education Act of 1994. http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003. htm. Accessed June 2012.
60. Whittaker P., Clarke J. J., San R. H., Betz J. M., Seifried H. E., de Jager L. S., Dunkel V. C.. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food Chem Toxicol. 2008 ; 46: 168-74